Keyword: Magenta Therapeutics
No fewer than five biotech IPOs debuted Thursday, raising more than $460 million and with more in the offing if underwriters take up further options.
Coming off the back of a healthy financing round just six weeks ago, stem cell biotech Magenta Therapeutics now wants more, and it wants to go public.
Atara hires ex-Genentech SVP to lead R&D, Semma names former Novartis CAR-T developer as CEO, and GSK's CFO heads for the exit.
Semma Therapeutics named Bastiano Sanna, formerly of Novartis’ cell and gene therapy unit and Magenta Therapeutics, as its president and CEO.
Celgene COO Scott Smith resigns, ex-Kite leaders Belldegrun and Chang form new CAR-T shop, GSK Dermatology exec jumps to Dermavant.
Jamie Macdonald succeeds Joseph von Rickenbach as Parexel CEO, Roche promotes William Pao to replace John Reed as pRED head, Moderna loses vaccines head.
Magenta could pay the German biotech up to $334 million in milestones if the antibody drug conjugate pacts hit their targets.
Magenta Therapeutics recruits Pfizer exec John Davis, M.D., as CMO; Teva veteran Siggi Olafsson re-emerges at Hikma Pharmaceuticals; and more.
John Davis, who headed early clinical development at Pfizer, joined Magenta Therapeutics.
Aron Knickerbocker will helm Five Prime, Hallberg becomes Sobi's general counsel, Truckenmiller promoted to EMD Serono's SVP.